Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609427 | 0.88 | KDM5B (0.48) | KDM5BNOTUMPRMT5GCGRKCNT1 | |
| SCHEMBL31517441 | 0.85 | GCGR (0.43) | KDM5BNOTUMPRMT5GCGRKCNT1 | |
| SCHEMBL31517572 | 0.81 | GCGR (0.43) | KDM5BNOTUMPRMT5GCGRKCNT1 | |
| SCHEMBL9133346 | 0.81 | KDM5B (0.43) | KDM5BNOTUMPRMT5GCGRMAPK10 | |
| SCHEMBL31517340 | 0.79 | LMNA (0.48) | KDM5BNOTUMPRMT5GCGRMAPK10 | |
| SCHEMBL31517207 | 0.79 | APP (0.43) | KDM5BNOTUMPRMT5GCGRKCNT1 | |
| SCHEMBL15930134 | 0.77 | HPGDS (0.48) | KDM5BNOTUMPRMT5GCGRMAPK10 | |
| SCHEMBL9134471 | 0.76 | NOTUM (0.47) | KDM5BNOTUMMAPK10PARP1PARP2 | |
| SCHEMBL27965655 | 0.75 | HPGDS (0.49) | NOTUMPRMT5GCGRMAPK10MAPT | |
| SCHEMBL14692465 | 0.75 | HPGDS (0.51) | NOTUMPRMT5MAPK10PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101018779-A | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | CN | disclosed |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1720860-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | disclosed |
| WO-2005080379-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRIN3A, GRM1 | KDM5B 2582/4885NOTUM 4056/4885PRMT5 792/4885 |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | KDM5B 2595/4885NOTUM 4132/4885PRMT5 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.